This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lalande, V Articles by Ji, B Search for Related Content PubMed PubMed Citation Articles by Lalande, V Articles by Ji, B

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 March; 37(3): 407-413

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.

Faculté de Médecine Pitié-Salpétrire, Paris, France.

ABSTRACT

The bactericidal activities of various monotherapies and combined regimens were compared in mice at different stages after infection with Mycobacterium tuberculosis. These therapies mimicked the initial and continuation phases of chemotherapy for human tuberculosis. As monotherapy, the bactericidal activity of sparfloxacin (SPFX) was dose related; the activity of SPFX at 100 mg/kg of body weight was comparable to that of rifampin (RMP) and was significantly greater than those of isoniazid (INH), pyrazinamide (PZA), or ofloxacin (OFLO) during both the initial and continuation phases of chemotherapy. During the initial phase, the addition of SPFX did not enhance or diminish the activities of the combinations INH-RMP-PZA or RMP-PZA; the combinations SPFX-PZA-streptomycin (SM) and SPFX-PZA-kanamycin (KANA) displayed powerful bactericidal activity. Because the area under the plasma concentration-time curve of SPFX (100 mg/kg) in mice is similar to that of SPFX (400 mg) in humans, the promising bactericidal activity displayed by SPFX in mice might be achieved in humans by administration of the drug in a clinically tolerated dosage. In addition, the combinations SPFX-PZA-SM and SPFX-PZA-KANA may be useful for the treatment of multidrug-resistant tuberculosis.

This article has been cited by other articles:

• Rosenthal, I. M., Zhang, M., Almeida, D., Grosset, J. H., Nuermberger, E. L. (2008). Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?. Am. J. Respir. Crit. Care Med. 178: 989-993 [Abstract] [Full Text]  
• Lounis, N., Gevers, T., Van Den Berg, J., Andries, K. (2008). Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse Model. Antimicrob. Agents Chemother. 52: 3568-3572 [Abstract] [Full Text]  
• Tasneen, R., Tyagi, S., Williams, K., Grosset, J., Nuermberger, E. (2008). Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 52: 3664-3668 [Abstract] [Full Text]  
• Rosenthal, I. M., Williams, K., Tyagi, S., Peloquin, C. A., Vernon, A. A., Bishai, W. R., Grosset, J. H., Nuermberger, E. L. (2006). Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 174: 94-101 [Abstract] [Full Text]  
• Pandey, R., Khuller, G. K. (2006). Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother 57: 1146-1152 [Abstract] [Full Text]  
• Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
• Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
• Hu, Y., Coates, A. R. M., Mitchison, D. A. (2003). Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: 653-657 [Abstract] [Full Text]  
• Dega, H., Bentoucha, A., Robert, J., Jarlier, V., Grosset, J. (2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob. Agents Chemother. 46: 3193-3196 [Abstract] [Full Text]  
• Lounis, N., Bentoucha, A., Truffot-Pernot, C., Ji, B., O'Brien, R. J., Vernon, A., Roscigno, G., Grosset, J. (2001). Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice. Antimicrob. Agents Chemother. 45: 3482-3486 [Abstract] [Full Text]  
• Lubasch, A., Erbes, R., Mauch, H., Lode, H. (2001). Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J 17: 641-646 [Abstract] [Full Text]  
• DANIEL, N., LOUNIS, N., JI, B., O'BRIEN, R. J., VERNON, A., GEITER, L. J., SZPYTMA, M., TRUFFOT-PERNOT, C., HEJBLUM, G., GROSSET, J. (2000). Antituberculosis Activity of Once-weekly Rifapentine-containing Regimens in Mice . Long-term Effectiveness with 6- and 8-Month Treatment Regimens. Am. J. Respir. Crit. Care Med. 161: 1572-1577 [Abstract] [Full Text]  
• Miyazaki, E., Miyazaki, M., Chen, J. M., Chaisson, R. E., Bishai, W. R. (1999). Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis. Antimicrob. Agents Chemother. 43: 85-89 [Abstract] [Full Text]  
• Ji, B., Lounis, N., Maslo, C., Truffot-Pernot, C., Bonnafous, P., Grosset, J. (1998). In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42: 2066-2069 [Abstract] [Full Text]  
• O'Brien, R. J., Vernon, A. A. (1998). New Tuberculosis Drug Development . How Can We Do Better?. Am. J. Respir. Crit. Care Med. 157: 1705-1707 [Full Text]  
• Williams, K. J., Chung, G. A. C., Piddock, L. J. V. (1998). Accumulation of Norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis. Antimicrob. Agents Chemother. 42: 795-800 [Abstract] [Full Text]  
• SIRGEL, F. A., BOTHA, F. J., PARKIN, D. P., VAN de WAL, B. W., SCHALL, R., DONALD, P. R., MITCHISON, D. A. (1997). The Early Bactericidal Activity of Ciprofloxacin in Patients with Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 156: 901-905 [Abstract] [Full Text]